We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Control of Gene Expression in Tumor Cell Mito

By Biotechdaily staff writers
Posted on 29 May 2002
Researchers have shown that the PRDX3 enzyme located in the mitochondria of tumor cells is a target of the well-known cancer-promoting gene, c-MYC. More...
Deregulated expression of the c-MYC transcription factor is found in a wide variety of human tumors.

Proteins made by the PRDX3 gene reduce oxidants called peroxides entering the cell. Investigators from John Hopkins University (Baltimore, MD, USA) used a method called chromatin immunoprecipitation analysis to precisely pinpoint protein binding and activation areas of the PRDX3 gene. The investigators found that the c-MYC gene was essential for activation of PRDX3. These findings were published in the May 14, 2002, issue of the Proceedings of the National Academy of Sciences.

The use of mitochondria-specific fluorescent probes also demonstrated that PRDX3 is essential for maintaining mitochondrial mass and membrane potential in transformed rat and human cells. To find out how c-MYC and PRDX3 work together, the scientists looked at different levels of PRDX3 activation in rat and human cancer cell lines where c-MYC was turned on. When PRDX3 was shut down, the mouse tumors stopped growing. When it was turned back on, the tumors grew rapidly.

"Think of PRDX3 as a light bulb and c-MYC as the light switch. If you remove the light bulb even though the switch may be on, the lamp still does not work,” explained Dr. Chi V. Dang. "In this case, we have removed the light bulb rendering the switch powerless.”

"These results show that changing PRDX3 activation can alter how tumors grow. Now, our challenge is to find out in which cancers this pathway is most important and what drugs may do the job,” said Dr. Dang.



Related Links:
Johns Hopkins University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.